Revance to Participate in Upcoming Investor Conferences
November 06 2023 - 7:00AM
Business Wire
Revance Therapeutics, Inc. (RVNC), today announced that the
company will be participating in the following investor
conferences.
Stifel 2023 Healthcare Conference Chief Financial
Officer, Tobin Schilke, is scheduled to participate in a fireside
chat on Tuesday, November 14, 2023, at 11:30 A.M. EST, in New York
City, New York.
Piper Sandler 35th Annual Healthcare Conference Chief
Executive Officer, Mark Foley, is scheduled to participate in a
fireside chat on Tuesday, November 28, 2023, at 3:00 P.M. EST, in
New York City, New York.
Interested parties can access the live audio webcasts for the
conferences from the Investor Relations section of the company's
website at www.revance.com. The webcast replays will be available
after the conclusion of the live presentations for approximately 90
days.
About Revance
Revance is a biotechnology company setting the new standard in
healthcare with innovative aesthetic and therapeutic offerings that
enhance patient outcomes and physician experiences. Revance’s
portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for
injection and the RHA® Collection of dermal fillers in the U.S.
Revance has also partnered with Viatris Inc. to develop a
biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun
Pharmaceutical to commercialize DAXXIFY® in China.
Revance is headquartered in Nashville, Tenn., with additional
office locations in Newark and Irvine, Calif.
Learn more at www.Revance.com, www.RevanceAesthetics.com,
www.DAXXIFY.com, www.hcp.DAXXIFYTherapy.com, or connect with us on
LinkedIn.
“Revance” and the Revance logo, and DAXXIFY® are registered
trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid®
and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered
trademark of Allergan, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106067994/en/
Investors Revance Therapeutics, Inc.: Jessica Serra,
510-279-6886 jessica.serra@revance.com or Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620 laurence@gilmartinir.com
Media Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476
sfahy@revance.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2024 to May 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From May 2023 to May 2024